Massachusetts Financial Services CO Y M Abs Therapeutics, Inc. Transaction History

Massachusetts Financial Services CO

  • $320 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024
BUY
$11.6 - $17.25 $32,016 - $47,610
2,760 Added 3.47%
82,202 $993,000
Q1 2024

May 14, 2024
SELL
$6.57 - $18.69 $1,149 - $3,270
-175 Reduced 0.22%
79,442 $1.29 Million
Q4 2023

Feb 08, 2024
SELL
$4.88 - $7.42 $12,268 - $18,653
-2,514 Reduced 3.06%
79,617 $542,000
Q3 2023

Nov 08, 2023
BUY
$4.86 - $7.23 $287,716 - $428,023
59,201 Added 258.18%
82,131 $447,000
Q2 2023

Aug 09, 2023
BUY
$5.68 - $10.34 $130,242 - $237,096
22,930 New
22,930 $155,000

Others Institutions Holding YMAB

# of Institutions
106
Shares Held
24.5M
Call Options Held
40.3K
Put Options Held
400
View Full List

About Y-mAbs Therapeutics, Inc.

YMAB Quotes by TradingView
  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email